|Bid||271.38 x 900|
|Ask||271.55 x 800|
|Day's Range||267.02 - 272.61|
|52 Week Range||223.25 - 468.55|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||14.04|
|Earnings Date||Oct 19, 2021 - Oct 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||417.70|
The drugmaker has started the process of submitting its Alzheimer’s disease therapy donanemab for approval.
Shares of Eli Lilly & Co. gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administration for its experimental Alzheimer's drug, donanemab. It also said it plans to conduct a Phase 3 clinical trial evaluating donanemab against Aduhelm, Biogen Inc.'s recently approved Alzheimer's drug, to assess "superiority of brain amyloid plaque clearance in early symptomati
Biogen (NASDAQ: BIIB) announced its third-quarter results on Wednesday. It's certainly true that Biogen did top analysts' estimates on both the top and bottom lines. Instead, there were three big problems with Biogen's Q3 results.